Following the consultee information meeting on Tuesday 27 January 2004 at which the appraisal scope was discussed, the Institute has accepted the consultees' recommendation to separate this appraisal into two parts. An appraisal of Etanercept and efalizimab for psoriasis will run along parallel timelines to an appraisal of Etanercept for psoriatic arthritis.

The final scopes for both appraisals are available on the Institute's website. It is anticipated that the guidance resulting from the two appraisals will be published separately in March 2005. The revised time lines for both technology appraisals are also available on the Institute's web site.